Incidence and patient baseline characteristics
colorectal neuroendocrine neoplasms, DSS
LUNG METASTASIS
From 1975 to 2019, there had been a steady rise in the incidence of CRNENs (
In this study, there were 668 patients with stage II-IV CRNENs recruited from 2010 to 2016 for prognostic analysis, among which males and females accounted for 53.3% and 46.7%, respectively. 20.7% of patients were ≥75 years old. 73.7% of patients were white, 14.5% and 11.8% were black and other races (American Indians/Alaskan Native Americans, Asians or Pacific Islanders and Unknown), respectively. The patients were divided into four groups based on histological grade: well differentiated (G I), moderately differentiated (G II), poorly differentiated (G III) and undifferentiated (G IV). We combined G I and G II into G I/II, G III and G IV into G III/IV for further analyses, which accounted for 48.4% and 51.6%, respectively. 65.1% of the lesion was located in the colon, and 34.9% showed up in the rectum. There were 17.7% of CRNENs patients in stage II, followed by 37.0% in stage III, and 45.4% in stage IV. The majority of patients (72.0%) underwent surgery, followed by 34.9% and 10.0% of them receiving chemotherapy or radiotherapy. The incidence of bone, brain, liver, and lung metastasis was 5.7%, 1.0%, 37.4%, and 5.1%, respectively. Our hospital diagnosed 62 CRNENs patients from 2009 to 2017, whose data was evaluated for independent validation. The baseline demographic features of all patients included in this study were shown in Clinicopathological characteristics of patients with stage II-IV CRNENs.* Others refer to American Indians/Alaskan Native Americans, Asians or Pacific Islanders and Unkonwn.CRNENs, colorectal neuroendocrine neoplasms; grade: well differentiated (G I), moderately differentiated (G II), poorly differentiated (G III) and undifferentiated (G IV); OS, overall survival; DSS, disease-specific survival; NA, not available.